This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pisters, P. W.T. Articles by Patel, S. R. Search for Related Content PubMed PubMed Citation Articles by Pisters, P. W.T. Articles by Patel, S. R. Social Bookmarking                            What's this?

Phase I Trial of Preoperative Concurrent Doxorubicin and Radiation Therapy, Surgical Resection, and Intraoperative Electron-Beam Radiation Therapy for Patients With Localized Retroperitoneal Sarcoma

Peter W.T. Pisters, Matthew T. Ballo, Mark J. Fenstermacher, Barry W. Feig, Kelly K. Hunt, Kevin A. Raymond, Michael A. Burgess, Gunar K. Zagars, Raphael E. Pollock, Robert S. Benjamin, Shreyaskumar R. Patel

From the Multidisciplinary Sarcoma Center at the University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Peter W.T. Pisters, MD, Department of Surgical Oncology, Unit 444, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009; email: ppisters{at}mdanderson.org.

Purpose: The primary objective of this phase I trial was to define the maximum-tolerated dose of external-beam radiation with concurrent fixed-dose continuous-infusion doxorubicin followed by surgical resection and electron-beam intraoperative radiation therapy (EB-IORT) for patients with localized, potentially resectable retroperitoneal sarcomas (RPS).

Patients and Methods: Thirty-five patients with radiographically resectable primary or recurrent intermediate- or high-grade RPS were treated. Doxorubicin was administered each week for 4 or 5 weeks as an initial bolus (4 mg/m²) followed by a 4-day continuous infusion (4 mg/m²/d). Concurrent radiation therapy was administered in escalating doses of 18.0, 30.6, 36.0, 41.4, 46.8, or 50.4 Gy in 1.8-Gy fractions. Radiographic restaging was performed 4 to 8 weeks after chemoradiation, and patients with localized disease underwent surgical resection with EB-IORT (15 Gy).

Results: Chemoradiation was completed as outpatient therapy in 31 patients (89%); four patients required hospital admission during chemoradiation or in the postchemoradiation preoperative period. At the highest radiation dose of 50.4 Gy, two (18%) of 11 patients had grade 3 or 4 nausea. Twenty-nine patients (83%) underwent laparotomy; six patients had interval disease progression and did not undergo surgery. Grossly complete resection (R0 or R1) was performed in 26 (90%) of 29 patients who had surgery. EB-IORT was feasible and successfully administered to 22 patients who had R0 or R1 resections.

Conclusion: Preoperative chemoradiation, surgical resection, and EB-IORT are feasible for patients with RPS. Preoperative external-beam radiation can be administered to a total dose of 50.4 Gy with continuous-infusion doxorubicin.

Supported by the University of Texas M.D. Anderson Cancer Center. There was no industry funding for this protocol.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Gronchi, S. Lo Vullo, M. Fiore, C. Mussi, S. Stacchiotti, P. Collini, L. Lozza, E. Pennacchioli, L. Mariani, and P. G. Casali Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients J. Clin. Oncol., January 1, 2009; 27(1): 24 - 30. [Abstract] [Full Text] [PDF]

				D. M. Thomas, A. Gronchi, and B. O'Sullivan A Multidisciplinary Approach to Retroperitoneal Sarcomas: Current State-of-the-Art ASCO Educational Book, January 1, 2009; 2009(1): 701 - 708. [Abstract] [Full Text] [PDF]

				M. Sonmezer and K. Oktay Fertility preservation in female patients Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266. [Abstract] [Full Text] [PDF]